Rossi, PA
Anthony M. Rossi, Trevose, PA US
Patent application number | Description | Published |
---|---|---|
20160002793 | COMPOSITIONS AND METHODS FOR INHIBITING CORROSION IN GAS TURBINE AIR COMPRESSORS - Methods and compositions are disclosed for inhibiting corrosion on metal surfaces of gas turbine air compressors. The methods comprise contacting the metal surfaces with a corrosion inhibiting composition comprising at least one filming amine. | 01-07-2016 |
Glenn T. Rossi, Ambler, PA US
Patent application number | Description | Published |
---|---|---|
20150115096 | Convertible Compounded Rotorcraft - A compound rotorcraft including a rotary wing aircraft having a fuselage and at least one rotor and a fixed-wing aircraft coupled to the rotary wing aircraft, wherein the rotary wing aircraft can fly on the rotor or the fixed-wing aircraft, and wherein the fixed-wing aircraft is detachable from the rotary wing aircraft to fly independently. | 04-30-2015 |
Jason Anthony Rossi, Collegeville, PA US
Patent application number | Description | Published |
---|---|---|
20090270374 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES - Bicyclic nitrogen containing compounds and their use as antibacterials. | 10-29-2009 |
Karen A. Rossi, Newtown, PA US
Patent application number | Description | Published |
---|---|---|
20090023702 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS - Novel compounds are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR 119 G protein-coupled receptor modulator therapy. These novel compounds have the structure Formula I or Formula IA. | 01-22-2009 |
20090036438 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS - The present invention provides a method for treating a thrombotic or an inflammatory disorder administering to a patient in need thereof a therapeutically effective amount of at least one compound of Formula (I) or Formula (V): | 02-05-2009 |
20090042919 | METHOD FOR MODULATING GPR119 G PROTEIN-COUPLED RECEPTOR AND SELECTED COMPOUNDS - A method of modulating the activity of the GPR119 G protein-coupled receptor comprising administering to a mammalian patient in need thereof a therapeutically effective amount of at least one compound of Formula I or Formula IA and, optionally, an additional therapeutic agent. | 02-12-2009 |
20110190327 | METHOD FOR MODULATING GPR119 G PROTEIN-COUPLED RECEPTOR AND SELECTED COMPOUNDS - A method of modulating the activity of the GPR119 G protein-coupled receptor comprising administering to a mammalian patient in need thereof a therapeutically effective amount of at least one compound of Formula I or Formula IA and, optionally, an additional therapeutic agent. | 08-04-2011 |
20110245227 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS - Novel compounds are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR119 G protein-coupled receptor modulator therapy. These novel compounds have the structure Formula I or Formula IA. | 10-06-2011 |
20110263548 | PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS - Novel compounds of structure Formula (I) or an enantiomer, a diastereomer, or a pharmaceutically acceptable salt thereof, wherein Z, R | 10-27-2011 |
20120041190 | MACROCYCLES AS FACTOR XIA INHIBITORS - The present invention provides compounds of Formula (I): | 02-16-2012 |
20120088758 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS - The present invention provides a method for treating a thrombotic or an inflammatory disorder administering to a patient in need thereof a therapeutically effective amount of at least one compound of Formula (I) or Formula (V): | 04-12-2012 |
20120232048 | METHOD FOR MODULATING GPR119 G PROTEIN-COUPLED RECEPTOR AND SELECTED COMPOUNDS - A method of modulating the activity of the GPR119 G protein-coupled receptor comprising administering to a mammalian patient in need thereof a therapeutically effective amount of at least one compound of Formula I or Formula IA and, optionally, an additional therapeutic agent. | 09-13-2012 |
20120258959 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS - Novel compounds are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR119 G protein-coupled receptor modulator therapy. These novel compounds have the structure Formula I or Formula IA. | 10-11-2012 |
20130131074 | PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS - Novel compounds of structure Formula I: | 05-23-2013 |
20140206706 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS - The present invention provides a method for treating a thrombotic or an inflammatory disorder administering to a patient in need thereof a therapeutically effective amount of at least one compound of Formula (I) or Formula (V): | 07-24-2014 |
20150112058 | MACROCYCLES AS FACTOR XIA INHIBITORS - The present invention provides compounds of Formula (I): | 04-23-2015 |
20150259297 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS - The present invention provides a method for treating a thrombotic or an inflammatory disorder administering to a patient in need thereof a therapeutically effective amount of at least one compound of Formula (I) or Formula (V): | 09-17-2015 |
Michael Rossi, Limerick, PA US
Patent application number | Description | Published |
---|---|---|
20140336195 | ARYLOXMETHYL CYCLOPROPANE DERIVATIVES AS PDE10 INHIBITORS - The present invention is directed to aryloxymethyl cyclopropane derivatives which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction. | 11-13-2014 |
Michael A. Rossi, Limerick, PA US
Patent application number | Description | Published |
---|---|---|
20090275515 | 2-HYDROXY-2-PHENYLTHIOPHENYLPROPIONAMIDES AS ANDROGEN RECEPTOR MODULATORS - Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HFV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents. | 11-05-2009 |
20100222321 | Inhibitors of akt activtiy - The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer. | 09-02-2010 |
20110082135 | INHIBITORS OF AKT ACTIVITY - The instant invention provides for substituted [1,2,4]triazolo[4,3-a]-1,5-naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms, preferably Akt1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity, especially Akt1 by administering the compound to a patient in need of treatment of cancer. | 04-07-2011 |
20110288090 | Inhibitors of AKT Activity - The instant invention provides for compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer. | 11-24-2011 |
20140303143 | BENZOXAZOLINONE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS - Disclosed are compounds of Formula (A) or a salt thereof, wherein “Het”, R | 10-09-2014 |
20140350002 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES - The present invention is directed to imidazopyridin-2-one derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR | 11-27-2014 |
Randy Rossi, Greensburg, PA US
Patent application number | Description | Published |
---|---|---|
20140108027 | APPARATUSES, SYSTEMS, AND METHODS FOR DELIVERING MEDICATIONS FROM A CENTRAL PHARMACY TO A PATIENT IN A HEALTHCARE FACILITY - Provided herein are various apparatuses, systems, and methods for improving the efficiency of medication distribution within a healthcare facility. In particular, embodiments may provide for dispensing medications needed and medications anticipated to be needed to an authorized medical person for administration to a patient in a healthcare facility. Medications that are anticipated to be needed may be predicted based on a number of factors. The medications may be gathered, transported, stored, staged, and dispensed using one or more of the components described herein. Combinations of the components may be implemented for a system to automate or partially automate the dispensing of medications from a central pharmacy of a healthcare facility to a patient. | 04-17-2014 |
20140278156 | METHOD AND APPARATUS FOR PREPARING AND MONITORING AN INTRAVENOUS FLUID BAG - An intravenous (IV) fluid monitoring system and method are provided to facilitate notification that a replacement IV fluid bag should be prepared. In this regard, an IV fluid monitoring system includes a bag sensing element carried by an IV fluid bag. The IV fluid monitoring system further includes first and second sensing elements positioned on opposite sides of the IV fluid bag and configured to interact with the bag sensing element. The first and second sensing elements are physically separate from the IV fluid bag. The bag sensing element and the first and second elements are positioned such that a line of sight between at least the first sensing element and the bag sensing element extends through the IV fluid within the IV fluid bag while the IV fluid bag is in a filled state. A method and apparatus are also provided to facilitate preparation of an IV fluid bag. | 09-18-2014 |
20140292476 | APPARATUSES, SYSTEMS, AND METHODS FOR STORING AND DISPENSING MEDICATION PROXIMATE A PATIENT - Provided herein are various apparatuses, systems, and methods for improving the efficiency of medication distribution within a healthcare facility. In particular, embodiments may provide for storing and dispensing medications to an authorized medical person for administration to a patient in a healthcare facility. A storage and dispensing system may include a housing defining a cavity, a door movable between an open and a closed position to provide access to the cavity, two or more receivers disposed within the cavity, a lock to lock the door in the closed position, and a user interface configured to receive a request for medications stored within the cavity. The medications may be configured to be presented to a user in response to a request for the medications, while unrequested medications remain inaccessible. | 10-02-2014 |
Robert Rossi, Mendenhall, PA US
Patent application number | Description | Published |
---|---|---|
20100098621 | PROCESS FOR MAKING TITANIUM DIOXIDE - The disclosure relates to a process for making titanium dioxide, comprising: reacting titanium tetrachloride with oxygen by contacting the titanium tetrachloride with the oxygen in a vapor phase reactor under mixing conditions and at an elevated temperature to form a gaseous product stream containing titanium dioxide; separating the titanium dioxide from the gaseous product stream to form a process stream; analyzing the process stream to detect a concentration of titanium tetrachloride in the process stream; comparing the concentration of titanium tetrachloride detected in the process stream to an aim point concentration; and modifying the oxidation conditions to restore or maintain the concentration of titanium tetrachloride in the process stream at the aim point. In one embodiment, the process further comprises contacting the gaseous product stream with silicon tetrachloride under mixing conditions and at an elevated temperature to at least partially encapsulate the titanium dioxide with a silicon-containing compound and separating the at least partially encapsulated titanium dioxide from the gaseous product stream and analyzing the process stream to detect a concentration silicon tetrachloride for comparison to a silicon tetrachloride aim point concentration so that the conditions for silicon tetrachloride contacting can be modified to restore or maintain the concentration of silicon tetrachloride in the process stream. | 04-22-2010 |